HC Wainwright Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $7.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 129.89% from the company’s current price.

Separately, EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Trading Down 2.4 %

Anixa Biosciences stock opened at $3.05 on Tuesday. The firm has a market capitalization of $97.99 million, a P/E ratio of -7.81 and a beta of 0.84. The stock has a fifty day moving average price of $3.26 and a 200 day moving average price of $2.99. Anixa Biosciences has a 52 week low of $2.14 and a 52 week high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, September 6th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. As a group, equities analysts predict that Anixa Biosciences will post -0.42 EPS for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently modified their holdings of ANIX. International Assets Investment Management LLC boosted its position in shares of Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after buying an additional 23,800 shares during the period. Westside Investment Management Inc. boosted its position in shares of Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the period. Tyler Stone Wealth Management boosted its holdings in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the last quarter. Concorde Asset Management LLC purchased a new position in Anixa Biosciences in the second quarter valued at about $31,000. Finally, Virtu Financial LLC purchased a new position in Anixa Biosciences in the third quarter valued at about $34,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.